Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714549 | 0.86 | KDM4E (0.53) | KDM4EALDH1A1SMN1; SMN2NPSR1LMNA | |
| SCHEMBL6616047 | 0.84 | MAPK1 (0.46) | AOC3ALDH1A1CYP3A4 | |
| SCHEMBL6341931 | 0.82 | AOC3 (0.43) | AOC3KDM4EALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL7817212 | 0.81 | AOC3 (0.40) | AOC3ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL25082792 | 0.81 | HTT (0.44) | AOC3KDM4EALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL10446374 | 0.81 | AOC3 (0.42) | AOC3KDM4EALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL25082789 | 0.81 | AOC3 (0.42) | AOC3KDM4EALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL13516155 | 0.78 | ALDH1A1 (0.46) | AOC3KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8316852 | 0.77 | XDH (0.40) | AOC3KDM4EALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL340356 | 0.76 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2NPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-11-25 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| WO-2020223536-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-9173424-B2 | Pyridine derivatives with umami flavour | GIVAUDAN S.A. (CH) | 2015-11-03 | — | — | US | disclosed |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN S.A. (CH) | 2014-10-02 | — | — | US | disclosed |
| EP-2451781-B1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012149157-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | GIVAUDAN SA (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2451781-A1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | Givaudan SA (CH) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004016-A1 | PYRIDINE DERIVATIVES WITH UMAMI FLAVOUR | GIVAUDAN SA (CH) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | AOC3 4124/4885KDM4E 4640/4885ALDH1A1 3472/4885 |
| US-20120277224-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | AOC3 2680/4885KDM4E 3115/4885ALDH1A1 3714/4885 |
| US-20120121783-A1 | Pyridine Derivatives With Umami Flavour | C5, CHRM1, C9 | AOC3 39/4885KDM4E 414/4885ALDH1A1 535/4885 |
| US-20140295045-A1 | Pyridine Derivatives With Umami Flavour | C5, CHRM1, C9 | AOC3 82/4885KDM4E 505/4885ALDH1A1 586/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | AOC3 4124/4885KDM4E 4640/4885ALDH1A1 3472/4885 |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | PASK, PDXK, PANK2 | AOC3 2680/4885KDM4E 3115/4885ALDH1A1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.